Abstract
To evaluate the therapeutic effects and systemic toxicities of a capecitabine-based home therapy regimen in patients with metastatic renal cell carcinoma, 30 patients were enrolled in a phase II clinical trial. Treatment consisted of oral capecitabine combined with subcutaneous recombinant human interferon-α 2a, recombinant human interleukin-2 and oral 13-cis-retinoic acid. There were two (7%) complete responses (CRs) and eight (27%) partial remissions (PRs), for an overall objective response rate of 34% (95% CI 17–53%). Except one, all responses are ongoing, with a median duration of 9+ and 8+ months for CRs and PRs, respectively. Additionally, 12 patients (40%) reached stable disease. Eight patients (27%) showed continued disease progression despite treatment. Therapy was well tolerated and was given in the outpatient setting. Capecitabine-related World Health Organization (WHO) grade 2 and 3 toxicities were observed in five and two patients respectively, and were limited to fatigue, nausea/vomiting, diarrhoea, stomatitis, dermatitis and hand-and-foot syndrome. The substitution of capecitabine for 5-FU in the pre-existing biochemotherapy regimen did not result in a reduced therapeutic efficacy and showed significant anti-tumour activity in patients with advanced renal cell carcinoma. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Atzpodien J, Lopez HE, Kirchner H, Bodenstein H, Pfreundschuh M, Rebmann U, Metzner B, Illiger HJ, Jakse G & Niesel T (1995 a) Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 13: 497–501
Atzpodien J, Kirchner H, Duensing S, Lopez HE, Franzke A, Buer J, Probst M, Anton P & Poliwoda H (1995 b) Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid. World J Urol 13: 174–177
Belldegrun A, Abi-Aad AS, Figlin RA & deKernion JB (1991) Renal cell carcinoma: basic biology and current approaches to therapy. Semin Oncol 18: 96–101
Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS & Griffin T (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17: 485–493
Budman DR, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, Behr J, Gordon RJ, Osterwalder B & Griffin T (1998) Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol 16: 1795–1802
Buer J, Probst M, Ganser A & Atzpodien J (1995) Response to 13-cis-retinoic acid plus interferon alpha2 in two patients with therapy refractory advanced renal cell carcinoma. J Clin Oncol 13: 2679–2680
Duensing S, Dallmann I, Grosse J, Buer J, Lopez HE, Deckert M, Storkel S, Kirchner H, Poliwoda H & Atzpodien J (1994) Immunocytochemical detection of P-glycoprotein: initial expression correlates with survival in renal cell carcinoma patients. Oncology 51: 309–313
Ellerhorst JA, Sella A, Amato RJ, Tu SM, Millikan RE, Finn LD, Banks M & Logothetis CJ (1997) Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer 80: 2128–2132
Frings S (1998) Capecitabine – a novel oral tumor activated fluoropyrimidine. Onkologie 21: 451–458
Hofmockel G, Theiss M, Gruss A, Langer W & Frohmuller H (1997) Immunochemotherapy of metastatic renal cell carcinoma with interleukin 2, interferon-alpha and 5-fluorouracil. Urologe A 36: 45–49
Hrusshesky WJ & Murphy GP (1977) Currents status of the therapy of advanced renal cell carcinoma. J Surg Oncol 9: 277–288
Ishikawa T, Fukase Y, Yamamoto T, Sekiguchi F & Ishitsuka H (1998 a) Antitumor activities of a novel fluoropyrimidine, N4-pentyloxycarbonyl-5′-deoxy-5-fluorocytidine (capecitabine). Biol Pharm Bull 21: 713–717
Ishikawa T, Sekiguchi F, Fukase Y, Sawada N & Ishitsuka H (1998 b) Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 58: 685–690
Joffe JK, Banks RE, Forbes MA, Hallam S, Jenkins A, Patel PM, Hall GD, Velikova G, Adams J, Crossley A, Johnson PW, Whicher JT & Selby PJ (1996) A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation. Br J Urol 77: 638–649
Lopez HE, Kirchner H & Atzpodien J (1996) Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 155: 19–25
Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, Reigner B, Griffin T, Kaye S & Verweij J (1998) Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 16: 2977–2985
Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I & Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34: 1274–1281
Motzer RJ, Schwartz L, Murray-Law T, Murphy BA, Hoffman AD, Albino AP, Vlamis V & Nanus DM (1995) Interferon alpha2 and cis-retinoic acid in renal cell carcinoma: Antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 13: 1950–1957
Quesada JR (1988) Biologic response modifiers in the therapy of metastatic renal cell carcinoma. Semin Oncol 15: 396–407
Roche Laboratories Inc. (1998) Xeloda (capecitabine) prescribing information. Roche Laboratories: USA
Schüller J, Cassidy J & Reigner B (1997) Tumor selective activation of Capecitabine in colorectal cancer patients. Onkologie 20: 189
Sella A, Kilbourn RG, Gray I, Finn L, Zukiwski AA, Ellerhorst J, Amato RJ & Logothetis CJ (1994) Phase I study of interleukin-2 combined with interferon-alpha and 5-fluorouracil in patients with metastatic renal cell cancer. Cancer Biother 9: 103–111
Takebayashi Y, Akiyama S, Akiba S, Yamada K, Miyadera K, Sumizawa T, Yamada Y, Murata F & Aikou T (1996) Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma [see comments]. J Natl Cancer Inst 88: 1110–1117
Tourani JM, Pfister C, Berdah JF, Benhammouda A, Salze P, Monnier A, Paule B, Guillet P, Chretien Y, Brewer Y, Di Palma M, Untereiner M, Malaurie E, Tadrist Z, Pavlovitch JM, Hauteville D, Mejean A, Azagury M, Mayeur D, Lucas V, Krakowski I, Larregain-Fournier D, Abourachid H, Andrieu JM & Chastang C Subcutaneous Administration Propeukin Program Cooperative Group (1998) Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. J Clin Oncol 16: 2505–2513
Warrel RP (1994) Applications for retinoids in cancer therapy. Semin Hematol 31: 1–13
Yagoda A, Abi-Rached B & Petrylak D (1995) Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin Oncol 22: 42–60
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Oevermann, K., Buer, J., Hoffmann, R. et al. Capecitabine in the treatment of metastatic renal cell carcinoma. Br J Cancer 83, 583–587 (2000). https://doi.org/10.1054/bjoc.2000.1340
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1340
Keywords
This article is cited by
-
Capecitabine induces hand-foot syndrome through elevated thymidine phosphorylase-mediated locoregional toxicity and GSDME-driven pyroptosis that can be relieved by tipiracil
British Journal of Cancer (2023)
-
A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer
Cancer Chemotherapy and Pharmacology (2010)
-
Interleukin-2/interferon-α2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)
British Journal of Cancer (2006)
-
Chemotherapy in metastatic renal cell cancer
World Journal of Urology (2005)
-
Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma
British Journal of Cancer (2004)